Plasma Proteomic Analysis May Identify New Markers for Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer

Xu Wei Cai, Kerby Shedden, Xiaoping Ao, Mary Davis, Xiao Long Fu, Theodore S. Lawrence, David M. Lubman, Feng Ming Kong

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Purpose: To study whether radiation induces differential changes in plasma proteomics in patients with and without radiation-induced lung toxicity (RILT) of Grade ≥2 (RILT2). Methods and Materials: A total of 57 patients with NSCLC received radiation therapy (RT) were eligible. Twenty patients, 6 with RILT2 with tumor stage matched to 14 without RILT2, were enrolled for this analysis. Platelet-poor plasma was obtained before RT, at 2, 4, 6 weeks during RT, and 1 and 3 months after RT. Plasma proteomes were compared using a multiplexed quantitative proteomics approach involving ExacTag labeling, reverse-phase high-performance liquid chromatography and nano-LC electrospray tandem mass spectrometry. Variance components models were used to identify the differential protein expression between patients with and without RILT2. Results: More than 100 proteins were identified and quantified. After excluding proteins for which there were not at least 2 subjects with data for at least two time points, 76 proteins remained for this preliminary analysis. C4b-binding protein alpha chain, Complement C3, and Vitronectin had significantly higher expression levels in patients with RILT2 compared with patients without RILT2, based on both the data sets of RT start to 3 months post-RT (p < 0.01) and RT start to the end of RT (p < 0.01). The expression ratios of patients with RILT2 vs. without RILT2 were 1.60, 1.36, 1.46, and 1.66, 1.34, 1.46, for the above three proteins, respectively. Conclusions: This proteomic approach identified new plasma protein markers for future studies on RILT prediction.

Original languageEnglish (US)
Pages (from-to)867-876
Number of pages10
JournalInternational Journal of Radiation Oncology Biology Physics
Volume77
Issue number3
DOIs
StatePublished - May 28 2010

Fingerprint

Non-Small Cell Lung Carcinoma
toxicity
Proteomics
markers
lungs
radiation therapy
grade
Radiotherapy
cancer
Radiation
Lung
proteins
radiation
Proteins
Complement C4b-Binding Protein
proteome
Vitronectin
Complement C3
liquid chromatography
Reverse-Phase Chromatography

Keywords

  • Non-small-cell lung cancer
  • biomarker
  • proteomics
  • radiation-induced lung toxicity

ASJC Scopus subject areas

  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Plasma Proteomic Analysis May Identify New Markers for Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer. / Cai, Xu Wei; Shedden, Kerby; Ao, Xiaoping; Davis, Mary; Fu, Xiao Long; Lawrence, Theodore S.; Lubman, David M.; Kong, Feng Ming.

In: International Journal of Radiation Oncology Biology Physics, Vol. 77, No. 3, 28.05.2010, p. 867-876.

Research output: Contribution to journalArticle

Cai, Xu Wei ; Shedden, Kerby ; Ao, Xiaoping ; Davis, Mary ; Fu, Xiao Long ; Lawrence, Theodore S. ; Lubman, David M. ; Kong, Feng Ming. / Plasma Proteomic Analysis May Identify New Markers for Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer. In: International Journal of Radiation Oncology Biology Physics. 2010 ; Vol. 77, No. 3. pp. 867-876.
@article{0f281134fa1948148c1f9024bad010e7,
title = "Plasma Proteomic Analysis May Identify New Markers for Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer",
abstract = "Purpose: To study whether radiation induces differential changes in plasma proteomics in patients with and without radiation-induced lung toxicity (RILT) of Grade ≥2 (RILT2). Methods and Materials: A total of 57 patients with NSCLC received radiation therapy (RT) were eligible. Twenty patients, 6 with RILT2 with tumor stage matched to 14 without RILT2, were enrolled for this analysis. Platelet-poor plasma was obtained before RT, at 2, 4, 6 weeks during RT, and 1 and 3 months after RT. Plasma proteomes were compared using a multiplexed quantitative proteomics approach involving ExacTag labeling, reverse-phase high-performance liquid chromatography and nano-LC electrospray tandem mass spectrometry. Variance components models were used to identify the differential protein expression between patients with and without RILT2. Results: More than 100 proteins were identified and quantified. After excluding proteins for which there were not at least 2 subjects with data for at least two time points, 76 proteins remained for this preliminary analysis. C4b-binding protein alpha chain, Complement C3, and Vitronectin had significantly higher expression levels in patients with RILT2 compared with patients without RILT2, based on both the data sets of RT start to 3 months post-RT (p < 0.01) and RT start to the end of RT (p < 0.01). The expression ratios of patients with RILT2 vs. without RILT2 were 1.60, 1.36, 1.46, and 1.66, 1.34, 1.46, for the above three proteins, respectively. Conclusions: This proteomic approach identified new plasma protein markers for future studies on RILT prediction.",
keywords = "Non-small-cell lung cancer, biomarker, proteomics, radiation-induced lung toxicity",
author = "Cai, {Xu Wei} and Kerby Shedden and Xiaoping Ao and Mary Davis and Fu, {Xiao Long} and Lawrence, {Theodore S.} and Lubman, {David M.} and Kong, {Feng Ming}",
year = "2010",
month = "5",
day = "28",
doi = "10.1016/j.ijrobp.2010.01.038",
language = "English (US)",
volume = "77",
pages = "867--876",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Plasma Proteomic Analysis May Identify New Markers for Radiation-Induced Lung Toxicity in Patients With Non-Small-Cell Lung Cancer

AU - Cai, Xu Wei

AU - Shedden, Kerby

AU - Ao, Xiaoping

AU - Davis, Mary

AU - Fu, Xiao Long

AU - Lawrence, Theodore S.

AU - Lubman, David M.

AU - Kong, Feng Ming

PY - 2010/5/28

Y1 - 2010/5/28

N2 - Purpose: To study whether radiation induces differential changes in plasma proteomics in patients with and without radiation-induced lung toxicity (RILT) of Grade ≥2 (RILT2). Methods and Materials: A total of 57 patients with NSCLC received radiation therapy (RT) were eligible. Twenty patients, 6 with RILT2 with tumor stage matched to 14 without RILT2, were enrolled for this analysis. Platelet-poor plasma was obtained before RT, at 2, 4, 6 weeks during RT, and 1 and 3 months after RT. Plasma proteomes were compared using a multiplexed quantitative proteomics approach involving ExacTag labeling, reverse-phase high-performance liquid chromatography and nano-LC electrospray tandem mass spectrometry. Variance components models were used to identify the differential protein expression between patients with and without RILT2. Results: More than 100 proteins were identified and quantified. After excluding proteins for which there were not at least 2 subjects with data for at least two time points, 76 proteins remained for this preliminary analysis. C4b-binding protein alpha chain, Complement C3, and Vitronectin had significantly higher expression levels in patients with RILT2 compared with patients without RILT2, based on both the data sets of RT start to 3 months post-RT (p < 0.01) and RT start to the end of RT (p < 0.01). The expression ratios of patients with RILT2 vs. without RILT2 were 1.60, 1.36, 1.46, and 1.66, 1.34, 1.46, for the above three proteins, respectively. Conclusions: This proteomic approach identified new plasma protein markers for future studies on RILT prediction.

AB - Purpose: To study whether radiation induces differential changes in plasma proteomics in patients with and without radiation-induced lung toxicity (RILT) of Grade ≥2 (RILT2). Methods and Materials: A total of 57 patients with NSCLC received radiation therapy (RT) were eligible. Twenty patients, 6 with RILT2 with tumor stage matched to 14 without RILT2, were enrolled for this analysis. Platelet-poor plasma was obtained before RT, at 2, 4, 6 weeks during RT, and 1 and 3 months after RT. Plasma proteomes were compared using a multiplexed quantitative proteomics approach involving ExacTag labeling, reverse-phase high-performance liquid chromatography and nano-LC electrospray tandem mass spectrometry. Variance components models were used to identify the differential protein expression between patients with and without RILT2. Results: More than 100 proteins were identified and quantified. After excluding proteins for which there were not at least 2 subjects with data for at least two time points, 76 proteins remained for this preliminary analysis. C4b-binding protein alpha chain, Complement C3, and Vitronectin had significantly higher expression levels in patients with RILT2 compared with patients without RILT2, based on both the data sets of RT start to 3 months post-RT (p < 0.01) and RT start to the end of RT (p < 0.01). The expression ratios of patients with RILT2 vs. without RILT2 were 1.60, 1.36, 1.46, and 1.66, 1.34, 1.46, for the above three proteins, respectively. Conclusions: This proteomic approach identified new plasma protein markers for future studies on RILT prediction.

KW - Non-small-cell lung cancer

KW - biomarker

KW - proteomics

KW - radiation-induced lung toxicity

UR - http://www.scopus.com/inward/record.url?scp=77952618694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952618694&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2010.01.038

DO - 10.1016/j.ijrobp.2010.01.038

M3 - Article

VL - 77

SP - 867

EP - 876

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -